Spectroscopy in Parkinson Disease

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study is to determine the utility of blood plasma infrared spectroscopy (biospectroscopy) in distinguishing subjects with idiopathic Parkinson's disease from healthy controls.

Detailed Description
-----------------
Oxidative stress has been implicated as a factor in the pathogenesis of Parkinson's disease (PD). The overall goal of this proposal is to use a novel metabolomics platform, based on near infrared biospectroscopy, to detect oxidatively modified blood plasma constituents. These spectral findings can be used to model the degree of oxidative stress with a modeled stress index that may distinguish PD cases from healthy elderly controls.

Official Title
-----------------
Evaluation of Blood Biospectroscopy as a Novel Diagnostic Test for Idiopathic Parkinson Disease

Conditions
-----------------
Parkinson Disease

Intervention / Treatment
-----------------
* Other: Blood draw


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PD Subjects: PostCEPT subjects with a diagnosis of PD based on UK Brain Bank criteria. Willing and able to provide informed consent. Healthy Controls: No current diagnosis or known history of a neurological disease/disorder. Non-blood relative of a patient or subject at the site who has diagnosis of PD (may include healthy controls from the PROBE study). No first degree relatives with diagnosis of PD MoCA score > 26. Age > 45. Willing and able to provide informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 46 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PostCEPT Subjects<br>Subjects with current Parkinson Disease Diagnosis currently enrolled in PostCEPT study | Other: Blood draw<br>* Blood draw, two tubes, used for isolation of cell-free blood plasma<br>|
| Control Subjects<br>Non-blood relatives of PostCEPT Subjects matched for age and other demographics | Other: Blood draw<br>* Blood draw, two tubes, used for isolation of cell-free blood plasma<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome of the study is the correct classification of cases of PD and controls. This will be quantified as sensitivity and specificity. |  | Baseline and annually for two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine impact of disease stage, age, gender, medications, cognitive scores, other laboratory measures (e.g. alpha-synuclein) and other clinical/demographic variables on plasma biospectra. |  | Baseline and annually for two years | 
| Correlate plasma biospectra with dopamine transporter neuroimaging data. |  | Baseline and annually for two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson Disease, blood, plasma, metabolomics, spectroscopy, oxidative stress.